<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 14pt"><B>Current Report</B></DIV>



<DIV align="center" style="font-size: 12pt; margin-top: 0pt"><B>Pursuant To Section&nbsp;13 or 15 (d)&nbsp;of the<BR>
Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported) &#151;April&nbsp;5, 2007</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>NUCRYST PHARMACEUTICALS CORP.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Alberta, Canada</B><BR>
(State or other jurisdiction <BR>
of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-51686</B><BR>
(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>Not Applicable</B><BR>
(I.R.S. Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>NUCRYST Pharmaceuticals Corp.<BR>
50 Audubon Road<BR>
Wakefield, MA 01880</B><BR>
(Address of principal executive offices)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(780)&nbsp;992-5626</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Not applicable</B><BR>
(Former name or former address, if changed since last report)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below):
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Item&nbsp;8.01</I></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Event.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please see Exhibit &#147;99.1&#148; attached
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Item&nbsp;9.01</I></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements and Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibits
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">99.1 &#151; Press Release &#147;NUCRYST Pharmaceuticals Annual General Meeting of Shareholders<B>&#148;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Nucryst Pharmaceuticals Corp.</B></FONT><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left"><B><I>/s/ Carol L. Amelio</I></B>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>Carol L. Amelio</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>Vice President, General Counsel and Corporate Secretary</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated: April&nbsp;9, 2007
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99.1
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><IMG src="o35717o3571700.gif" alt="(NUCRYST LOGO)">
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 6pt"><B>NUCRYST Pharmaceuticals Corp.</B>
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>Annual General Meeting of Shareholders</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Thursday, May&nbsp;3, 2007<BR>
Kellogg Room<BR>
Hilton Boston Financial District<BR>
89 Broad St., Boston, MA<BR>
10:00&nbsp;a.m. EDT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">NUCRYST Pharmaceuticals Corp. will hold its Annual General Meeting of Shareholders and
Investor Briefing on Thursday, May&nbsp;3, 2007 at 10:00&nbsp;a.m. EDT. The meeting will be held at the
Hilton Boston Financial District, Kellogg Room, 89 Broad Street in Boston. An agenda has been
posted on the NUCRYST website, <U>www.nucryst.com</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Both the meeting and investor briefing will be webcast live at <U>www.nucryst.com</U>. An audio file of
the webcast will be archived and posted on the NUCRYST website.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical
products that fight infection and inflammation using its patented atomically disordered
nanocrystalline silver technology. Smith &#038; Nephew plc sell a range of advanced wound care products
under their Acticoat&#153; trade mark: Acticoat&#153; products incorporate NUCRYST&#146;s SILCRYST&#153; coatings and
are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address
medical conditions that are characterized by both infection and inflammation. The Company has
developed its proprietary nanocrystalline silver in a powder form for use as an active
pharmaceutical ingredient, referred to as NPI 32101.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A more detailed discussion of NUCRYST&#146;s 2006&nbsp;year end results can be found in the 2006 Consolidated
Financial Statements and Management&#146;s Discussion and Analysis, which are available at <U>www.sec.gov</U>
and <U>www.sedar.com</U> and in NUCRYST&#146;s 2006 Annual Report on Form 10-K, which will be available on the
same websites. NUCRYST filings are also available at <U>www.nucryst.com/Regulatory_Filings.htm</U>.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For more information, please contact:<BR>
Gillian McArdle<BR>
416-504-8464<BR>
<U>info@nucryst.com</U>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "o35717e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11214}]
{"company-data": {"conformed-name": "NUCRYST Pharmaceuticals Corp.", "cik": "0001344674", "assigned-sic": "3841", "irs-number": "000000000", "state-of-incorporation": "A0", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51686", "film-number": "07759438"}, "business-address": {"street1": "50 AUDUBON ROAD", "street2": "SUITE B", "city": "WAKEFIELD", "state": "MA", "zip": "01880", "phone": "781-224-1444"}, "mail-address": {"street1": "50 AUDUBON ROAD", "street2": "SUITE B", "city": "WAKEFIELD", "state": "MA", "zip": "01880"}}
e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant To Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) —April 5, 2007
NUCRYST PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Alberta, Canada
(State or other jurisdiction
of incorporation or organization)
000-51686
(Commission File Number)
Not Applicable
(I.R.S. Employer Identification No.)
NUCRYST Pharmaceuticals Corp.
50 Audubon Road
Wakefield, MA 01880
(Address of principal executive offices)
Registrant's telephone number, including area code:
(780) 992-5626
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 8.01
Other Event.
Please see Exhibit "99.1" attached
Item 9.01
Financial Statements and Exhibits
Exhibits
99.1 — Press Release "NUCRYST Pharmaceuticals Annual General Meeting of Shareholders
"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Nucryst Pharmaceuticals Corp.
By:
/s/ Carol L. Amelio
Carol L. Amelio
Vice President, General Counsel and Corporate Secretary
Dated: April 9, 2007
Exhibit 99.1
NUCRYST Pharmaceuticals Corp.
Annual General Meeting of Shareholders
Thursday, May 3, 2007
Kellogg Room
Hilton Boston Financial District
89 Broad St., Boston, MA
10:00 a.m. EDT
NUCRYST Pharmaceuticals Corp. will hold its Annual General Meeting of Shareholders and
Investor Briefing on Thursday, May 3, 2007 at 10:00 a.m. EDT. The meeting will be held at the
Hilton Boston Financial District, Kellogg Room, 89 Broad Street in Boston. An agenda has been
posted on the NUCRYST website,
www.nucryst.com
.
Both the meeting and investor briefing will be webcast live at
www.nucryst.com
. An audio file of
the webcast will be archived and posted on the NUCRYST website.
NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical
products that fight infection and inflammation using its patented atomically disordered
nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products
under their Acticoat™ trade mark: Acticoat™ products incorporate NUCRYST's SILCRYST™ coatings and
are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address
medical conditions that are characterized by both infection and inflammation. The Company has
developed its proprietary nanocrystalline silver in a powder form for use as an active
pharmaceutical ingredient, referred to as NPI 32101.
A more detailed discussion of NUCRYST's 2006 year end results can be found in the 2006 Consolidated
Financial Statements and Management's Discussion and Analysis, which are available at
www.sec.gov
and
www.sedar.com
and in NUCRYST's 2006 Annual Report on Form 10-K, which will be available on the
same websites. NUCRYST filings are also available at
www.nucryst.com/Regulatory_Filings.htm
.
-30-
For more information, please contact:
Gillian McArdle
416-504-8464
info@nucryst.com